Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period, specifying the contract end date, and updating the counterparty disclosure schedule to August 1, 2031, at the customer’s request regarding the contract manufacturing agreement originally disclosed on November 28, 2019. 📊 [Key Disclosure Details…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period, specifying the contract end date, and updating the counterparty disclosure schedule to March 8, 2033, at the customer’s request regarding the contract manufacturing agreement originally disclosed on April 26, 2019. 📊 [Key Disclosure Details…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period, specifying the contract end date, and updating the counterparty disclosure schedule to March 8, 2033, at the customer’s request regarding the contract manufacturing agreement originally disclosed on May 14, 2019. 📊 [Key Disclosure Details…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period, specifying the contract end date, and updating the counterparty disclosure schedule to August 1, 2031, at the customer’s request regarding the contract manufacturing agreement originally disclosed on November 28, 2023. 📊 [Key Disclosure Details…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is additionally listing 21,815 common shares on November 14, 2025, following the exercise of stock options by employees. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional Listing Execution on Scheduled Date (November 14, 2025) This disclosure…

Read More “[Disclosure] Celltrion (068270) – Additional Listing (Exercise of Stock Options) / 2025-11-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure increasing the contract amount from approx. KRW 198.5B to approx. KRW 275.1B and extending the contract period and disclosure postponement period to December 31, 2034, at the customer’s request regarding the contract manufacturing agreement originally disclosed on May 26,…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-06” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN resolved to submit an agenda for conditional delisting from the KOSDAQ market to the Extraordinary General Meeting of Shareholders (EGM) on December 8, 2025, for the purpose of transferring its listing to the KOSPI market. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s…

Read More “[Disclosure] ALTEOGEN (196170) – Resolution on Submission of Agenda for Approval of Delisting / 2025-11-06” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will hold an Extraordinary General Meeting of Shareholders (EGM) on December 8, 2025, at the Daejeon Convention Center to vote on the approval of conditional delisting from KOSDAQ and transfer listing to KOSPI. Electronic voting will also be conducted. 📊 [Key Disclosure Details & Major…

Read More “[Disclosure] ALTEOGEN (196170) – Resolution on Convocation of Extraordinary General Meeting of Shareholders / 2025-11-06” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN set November 21, 2025, as the record date to determine eligible shareholders for its upcoming Extraordinary General Meeting of Shareholders (EGM). 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Shareholder Determination and EGM Convocation Notice This…

Read More “[Disclosure] ALTEOGEN (196170) – Closure of Register of Shareholders or Setting of Record Date / 2025-11-06” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure substantially increasing the contract amount from approx. KRW 242.0B to approx. KRW 517.9B and extending the contract period and disclosure postponement period to December 31, 2033, at the customer’s request regarding the contract manufacturing agreement originally disclosed on May…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-04” »